Matches in SemOpenAlex for { <https://semopenalex.org/work/W2178446093> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2178446093 endingPage "2110" @default.
- W2178446093 startingPage "2103" @default.
- W2178446093 abstract "PURPOSE To determine the toxicity and immunologic activity of an antiidiotype melanoma vaccine that consists of monoclonal antibody I-Mel-2 (MELIMMUNE-2, IDEC Pharmaceuticals, La Jolla, CA) and an immunologic adjuvant SAF-m. PATIENTS AND METHODS Twenty-six patients with metastatic melanoma, 17 of whom had previously received chemotherapy, were given 2 mg of I-Mel-2 and either 100 micrograms (n = 6) or 250 micrograms (n = 20) of SAF-m. Antiidiotype vaccine was given intramuscularly (IM) biweekly for 4 weeks, and then bimonthly until disease progression. Human antimurine antibodies (HAMA), anti-I-Mel-2 antibodies, and specific antibody (Ab)3 against the melanoma epitope mimicked by the vaccine were titrated before treatment, biweekly from weeks 4 to 12, and every 4 to 8 weeks thereafter. Computed tomographic (CT) scans of the chest, abdomen, and pelvis and magnetic resonance imaging (MRI) of the brain were obtained before and bimonthly during treatment to evaluate responses. RESULTS Elevated titers of human antimouse antibodies and anti-I-Mel-2 antibodies were associated with clinical antitumor effect (P = .02 and P = .05, respectively). Ab3 was absent in most patients, but was found in the best clinical responder. Fever, myalgias/arthralgias, fatigue, nausea, and headaches were the most common toxicities. Grade III myalgias/arthralgias and headaches required dose reduction of SAF-m in eight patients at the 250-microgram dose. No treatment-related death occurred. Six patients had an antitumor effect: one complete response in liver and lung, two minor responses, and three stable disease. The patient with a complete response has survived nearly 5 years. CONCLUSION I-Mel-2 antiidiotype vaccine was safe, tolerated best at the 100-microgram dose of SAF-m, and had immunologic and clinical activity." @default.
- W2178446093 created "2016-06-24" @default.
- W2178446093 creator A5013556625 @default.
- W2178446093 creator A5034626563 @default.
- W2178446093 creator A5036493105 @default.
- W2178446093 creator A5052891844 @default.
- W2178446093 creator A5059634145 @default.
- W2178446093 creator A5067387322 @default.
- W2178446093 creator A5068666680 @default.
- W2178446093 date "1997-05-01" @default.
- W2178446093 modified "2023-10-14" @default.
- W2178446093 title "Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m." @default.
- W2178446093 cites W1594366792 @default.
- W2178446093 cites W1771243425 @default.
- W2178446093 cites W1904436785 @default.
- W2178446093 cites W1998121629 @default.
- W2178446093 cites W2009642161 @default.
- W2178446093 cites W2009754926 @default.
- W2178446093 cites W2026599056 @default.
- W2178446093 cites W2034750454 @default.
- W2178446093 cites W2081774451 @default.
- W2178446093 cites W2098072496 @default.
- W2178446093 cites W2103631621 @default.
- W2178446093 cites W2105320220 @default.
- W2178446093 cites W2111265483 @default.
- W2178446093 cites W2133514770 @default.
- W2178446093 cites W2149177848 @default.
- W2178446093 cites W2216821117 @default.
- W2178446093 cites W2239850217 @default.
- W2178446093 cites W2337157181 @default.
- W2178446093 cites W2397387908 @default.
- W2178446093 cites W2414900721 @default.
- W2178446093 doi "https://doi.org/10.1200/jco.1997.15.5.2103" @default.
- W2178446093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9164224" @default.
- W2178446093 hasPublicationYear "1997" @default.
- W2178446093 type Work @default.
- W2178446093 sameAs 2178446093 @default.
- W2178446093 citedByCount "34" @default.
- W2178446093 countsByYear W21784460932012 @default.
- W2178446093 countsByYear W21784460932013 @default.
- W2178446093 crossrefType "journal-article" @default.
- W2178446093 hasAuthorship W2178446093A5013556625 @default.
- W2178446093 hasAuthorship W2178446093A5034626563 @default.
- W2178446093 hasAuthorship W2178446093A5036493105 @default.
- W2178446093 hasAuthorship W2178446093A5052891844 @default.
- W2178446093 hasAuthorship W2178446093A5059634145 @default.
- W2178446093 hasAuthorship W2178446093A5067387322 @default.
- W2178446093 hasAuthorship W2178446093A5068666680 @default.
- W2178446093 hasConcept C121608353 @default.
- W2178446093 hasConcept C126322002 @default.
- W2178446093 hasConcept C141071460 @default.
- W2178446093 hasConcept C159654299 @default.
- W2178446093 hasConcept C203014093 @default.
- W2178446093 hasConcept C2777701055 @default.
- W2178446093 hasConcept C2777863537 @default.
- W2178446093 hasConcept C2780580376 @default.
- W2178446093 hasConcept C71924100 @default.
- W2178446093 hasConcept C90924648 @default.
- W2178446093 hasConceptScore W2178446093C121608353 @default.
- W2178446093 hasConceptScore W2178446093C126322002 @default.
- W2178446093 hasConceptScore W2178446093C141071460 @default.
- W2178446093 hasConceptScore W2178446093C159654299 @default.
- W2178446093 hasConceptScore W2178446093C203014093 @default.
- W2178446093 hasConceptScore W2178446093C2777701055 @default.
- W2178446093 hasConceptScore W2178446093C2777863537 @default.
- W2178446093 hasConceptScore W2178446093C2780580376 @default.
- W2178446093 hasConceptScore W2178446093C71924100 @default.
- W2178446093 hasConceptScore W2178446093C90924648 @default.
- W2178446093 hasIssue "5" @default.
- W2178446093 hasLocation W21784460931 @default.
- W2178446093 hasLocation W21784460932 @default.
- W2178446093 hasOpenAccess W2178446093 @default.
- W2178446093 hasPrimaryLocation W21784460931 @default.
- W2178446093 hasRelatedWork W113810927 @default.
- W2178446093 hasRelatedWork W1586374228 @default.
- W2178446093 hasRelatedWork W2003938723 @default.
- W2178446093 hasRelatedWork W2047967234 @default.
- W2178446093 hasRelatedWork W2118496982 @default.
- W2178446093 hasRelatedWork W2364998975 @default.
- W2178446093 hasRelatedWork W2369162477 @default.
- W2178446093 hasRelatedWork W2439875401 @default.
- W2178446093 hasRelatedWork W4238867864 @default.
- W2178446093 hasRelatedWork W2525756941 @default.
- W2178446093 hasVolume "15" @default.
- W2178446093 isParatext "false" @default.
- W2178446093 isRetracted "false" @default.
- W2178446093 magId "2178446093" @default.
- W2178446093 workType "article" @default.